Hubert Senters here.
Let’s take a look at BIIB. Now heads up you’re going to think I’m skeptical on this stuff. I’m not skeptical. It’s just when we’re trying to cure diseases like just any disease in general that’s harder to cure when they go through trials. A lot of stocks will get smashed when they can’t fix a drug for that.
And I know we’re all trying to figure out how to cure all Tyler and cancer and stuff like that. Unfortunately, the latter is usually what happens. This right here like you get a trial gone bad and the thing will gap down and get just absolutely destroyed so and this has been done time and time again so just be careful when you’re in Biogen stocks or drug stocks and stuff like that.
If you’re doubling down on your hopes that it’s going to be the cure for cancer and hopefully, one day they’ll kick it through our ass, right. But it’s not an investment it’s a gamble because it’s so hard to do so be careful when you’re in this stuff because I don’t want you to get hurt and being a stock at like $320 and then the next day it gaps down to $226.
But they do make decent trading opportunities but you have to wait until for the trial fails so just be careful on this stuff but you do have a potential bracket trade here on BIIB. Just bracket trade that boy and see if you can get some profit out of it above $236 would be a long below $224 would be a short and make sure that you understand the risk reward ratio when you’re investing in drug stocks, genetic stocks and bio biology and pharmaceutical stuff like that just because it’s a little bit more risky if they just don’t pass a trial so just be careful on this stuff.
I’m going to be doing a special webinar tomorrow at noon on risk reward ratios and how to trade bonds and notes. I’m going to hyperlink you to that form. Smash it big yellow button that says CLAIM MY SPOT NOW to register for the webinar tomorrow at 12PM EST. I’ll see you then.
Good luck. Hope it helps. And I’ll see you on the next video.
Hubert.
